Skip to content

Author

Erica Pietroluongo

We have 2 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Role of maintaining the TKI backbone in oncogene-driven NSCLC after progression.

Tyrosine kinase inhibitors (TKIs) have marked a turning point in the treatment of oncogene-addicted non-small cell lung cancer (NSCLC), offering unprecedented efficacy. Yet, most tumors eventually develop resistance and progress, often prompting discontinuation of the targeted agent and a switch to non-targeted therapi...

Francesca Piazza, Rishi Sharma, Alessandra Esposito et al. · 0 citations
Review Open access Sep 2026

The next-generation biomarkers in early-stage triple negative breast cancer.

Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.

Federica Falcone, E. Pietroluongo, P. De Placido · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.